The US Food and Drug Administration (USFDA) has given Zydus Lifesciences final approval to market Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg.
Topiramate Extended-Release capsules are prescribed to treat epilepsy patients’ seizure control and prevention needs. It may also be used to stop migraines from occurring. The group’s formulation manufacturing facility in Ahmedabad SEZ, India, will produce the medication.
According to IQVIA data, topiramate Extended-Release capsule had yearly sales of USD 68.8 million in the United States.